Topical azole antifungal
Pregnancy: Compatible — considered safe for topical use throughout pregnancy.
Clotrimazole 1% Cream / Solution
Brand names: Canesten (1% cream, 1% solution, powder spray)
Adult dose
Dose: Apply 2–3 times daily to affected areas
Route: Topical
Frequency: Two to three times daily
Max: Apply to affected area and surrounding skin
Tinea pedis, cruris, corporis, and candidal skin infections. Apply twice to three times daily for 2–4 weeks. Continue for 2 weeks after clinical clearance to prevent relapse. Also effective for pityriasis versicolor.
Paediatric dose
Route: Topical
Frequency: 2–3 times daily
Max: Apply to affected area
Concentration: 1% cream or solution Application/ml
Safe for use in all ages including neonates for candidal nappy rash. In neonates: apply after each nappy change.
Dose adjustments
Renal
N/A — topical use.
Hepatic
N/A — topical use.
Clinical pearls
- Broad-spectrum coverage: effective against dermatophytes (tinea), Candida, and Malassezia (pityriasis versicolor)
- Widely available OTC — patients may self-treat before presentation; confirm correct diagnosis before prescribing systemic antifungals
- Canesten HC (clotrimazole + hydrocortisone): for inflammatory tinea or candidal intertrigo — short course only (max 7 days) to avoid steroid complications
- Neonatal candidal nappy rash: apply to affected area after each nappy change until 7 days after clearance
- Treatment duration: tinea corporis/cruris 2–4 weeks; tinea pedis 4 weeks; candida 2–4 weeks
Contraindications
- Hypersensitivity to clotrimazole or imidazoles
Side effects
- Local burning and irritation
- Skin rash (rare contact dermatitis)
- Erythema at application site
Interactions
- No significant systemic interactions with topical use
- May damage latex condoms/diaphragms (genital use)
Monitoring
- Clinical response at 2 weeks
- Signs of secondary bacterial infection
Reference: BNFc; BNF; NICE CKS Fungal Skin Infection; BAD Dermatophyte Infection Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD